INTRODUCTION

Role of tumor heterogeneity in tumor progression
Cutaneous melanoma is a highly aggressive malignancy, which often gives rise to metastases and local recurrences following series of tumor-free staging [1, 2] . The histopathological examination of excisional and re-excisional samples together with sentinel lymph node biopsies constitutes a fundamental part of the prognostic evaluation of this disease. Thus, the ability to detect recurrent-tumor-initiating cells in the tissue sample is highly important for prognostic purposes as well as managing this disease.
As a result of tumor heterogeneity, tumor cells often differentially express phenotypic markers [3, 4] , rendering their detection during routine histological assessments difficult.
Epithelial-mesenchymal transition, dedifferentiation and acquisition of stem-cell characteristics have been shown to make tumor cells more malignant [3, 5, 6] . Although the mechanisms by which these features are acquired have not yet been fully elucidated, epigenomic and genomic alterations are thought to be the key drivers for malignant heterogeneity [7, 8] .
Cell fusion in malignancies
An increasing body of evidence indicates that cell fusion has not only a physiological role during tissue development and repair, but might also be a hidden force promoting tumor progression [9] [10] [11] [12] [13] . Fibroblasts, mesenchymal stem cells and macrophages have been proposed as fusion partners of tumor cells [14] [15] [16] and several studies have demonstrated that tumor-stromal hybrid cells mostly display more malignant properties than parental tumor cells [17, 18] .
Investigation of spontaneous and induced cell fusion events
Most cell fusion studies are based on experiments on hybrid cells that originate from a single hybrid clone generated with electro-or chemical fusion followed by antibiotic selection.
There are only a few studies focusing on spontaneous cell-cell fusion, which is a wellprogrammed event that requires a specific controlling system [19] . By artificially generating hybrid cells, there is the possibility that unique and important characteristics of hybrid cells 7 might not be discovered. Furthermore, precise analysis of hybrid cell morphology and phenotype might also differ in spontaneous and programmed events.
Cell fusion as a potential mechanism contributing to tumor heterogeneity
Numerous studies have suggested that cell fusion may contribute to tumor heterogeneity [20] [21] [22] [23] 
MATERIALS & METHODS
Cell Culture
The human melanoma cell lines A375, G361, UACC-257, and SK-MEL-2 were kindly provided by Krisztina Buzás. All cell lines were authenticated using short tandem repeat analysis (Microsynth AG, Balgach, Switzerland) after finishing all experiments. Primary human monocytes were obtained from peripheral blood and isolated using MagCellect Human CD14+ Cell Isolation Kit (R&D Systems, Minneapolis, MN, USA) following gradient centrifugation with Ficoll-Paque (GE Healthcare Life Sciences, Chalfont St Giles, UK).
Human dermal fibroblasts were obtained from healthy individuals undergoing plastic surgery with the approval of the local institutional review board and after signing an informed consent. Skin samples were incubated in dispase solution overnight at 4 °C. After the removal of the epidermis, the dermis was incubated in a digestion medium (10.8 mg collagenase, 5 mg hyaluronidase, 0.4 mg deoxyribonuclease, and 0.1 mL fetal bovine serum diluted in 4 mL DMEM low glucose medium) for two hours at 37 °C and filtered through a 100-µm cell strainer.
Each melanoma cell line stained with 6 µmol/mL CellTracker Orange (CMTMR) was mixed either with fibroblasts or with freshly isolated monocytes labeled with 10 and 4 µmol/mL CellTracker Green (CMFDA, both from Life Technologies, Carlsbad, CA, USA), respectively, and grown in co-cultures for 24 h. The fibroblast-containing co-cultures were grown in low glucose DMEM supplemented with 5% fetal bovine serum, while the monocyte-containing co-cultures in RPMI 1640 (HEPES modification) with 10% fetal bovine serum and 30 IU/mL GMCSF (R&D Systems). All growth media were supplemented with 1% Penicillin/Streptomycin and 1% Glutamine. All cell culture reagents used are products of Lonza (Basel, Switzerland), if not specified otherwise. 
Fluorescent live cell imaging
Co-cultures grown for 12 h were put into the chamber of a Fluoview 10i-W confocal laserscanning microscope (Olympus). Excitation/emission wavelengths were 473/519 and 559/567 nm for CTG and CTO, respectively. Five Z-stack images with 3-µm step sizes were taken every 60 min for 12 h at 90 randomly chosen regions using 60× magnification.
Measurement of cell fusion rates
Co-cultures fixed with PFA and stained with DAPI were analyzed in a CyFlow® Space flow cytometer (Sysmex Partec GmbH, Görlitz, Germany). DAPI, CellTracker Green, and
CellTracker Orange were detected on channels FL10, FL1, and FL12, respectively. Gating is shown in Figure 1 .
Figure 1. Gating mechanisms in flow cytometry for the measurement of cell fusion rates.
Representative dot plots of an A375-monocyte co-culture. In the forward scatter (FSC) -side scatter (SSC) plot (left panel) cell debris is excluded upon gating the events in the upper right quadrant. In the FL10-A -FL10-W plot (middle panel) only the FSC+/SSC+ events are displayed. FL10-A− cells are considered as apoptotic cells while FL10-W+ cells as cell doublets and are therefore excluded. Only FL10-A+/ FL10-W− cells are displayed in the CellTracker Green (CTG) -CellTracker Orange (CTO) plot (right panel), in which CTG+/CTO− cells are monocytes and CTG−/CTO+ cells are melanoma cells.
Assuming that double positive cells in a co-culture result not only from cell fusion, we used transwell cultures for controls, in which monocytes were separated from melanoma cells by a Transwell® (Corning) with a pore size of 3.0 µm; thus, small, stained dead cell particles could cross the membrane but intact cells could not fuse. Therefore, fusion rate was determined as the rate of double positive cells detected in transwell cultures subtracted from that of co-cultures. All data were analyzed using FlowJo software (FlowJo, Ashland, OR, USA).
Immunofluorescent staining
Co-cultures were fixed with PFA. High (for MART1) or low (for CD68) pH target retrieval solution (DAKO, Glostrup, Denmark) was used for heat-induced epitope retrieval. 50% heatinactivated serum of the monocyte donor was used to block Fc receptors on monocytes and Immunofluorescent stainings were visualized with epifluorescent microscopy.
Excitation/emission filters were set to 653/668 nm for Alexa 647.
Tissue Samples and Determination of BRAF Mutational Status
Tissue samples from n = 11 patients with BRAF V600E and n = 5 patients with BRAF WT melanoma were examined for BRAF V600E protein expression. The corresponding patient numbers for genetic analyses were n = 11 in the case of BRAF V600E melanoma and n = 8 in the case of BRAF WT melanoma. The BRAF mutational status of melanomas was determined with cobas® 4800 BRAF V600 Mutation Test (Roche Molecular Diagnostics, Pleasanton, CA, USA). respectively, using laser-capture microdissection (Figure 4a,b) . Subsequent allele specific mutation detection PCR analyses performed on the dissected stromal cells revealed that the BRAF V600E mutant allele was present in peritumoral MART1−/SMA+ fibroblasts and MART1−/CD68+ macrophages. In addition to primary melanoma tissue samples, such peritumoral stromal cells carrying the melanoma-derived mutation were detected in lymph node and cutaneous melanoma metastases (Figure 4c) . Surprisingly, BRAF V600E was also detected when analyzing MART1− macrophages dissected from a histologically tumor-free re-excision sample from a patient who subsequently developed a local recurrence. 
Immunohistochemistry
Melanoma cells spontaneously fuse with fibroblasts and monocytes in vitro
In order to investigate how cells displaying a stromal phenotype and containing melanomaderived genetic information could form, we co-cultured various human melanoma cell lines either with primary human dermal fibroblasts or with freshly isolated human monocytes for 24 hours. CellTracker Orange (CTO) and CellTracker Green (CTG) fluorescent vital dyes were used to identify melanoma cells and fibroblasts or monocytes, respectively ( Figure 5 ).
Figure 5. In vitro cell fusion model. Primary human dermal fibroblasts (left) or human peripheral blood-derived monocytes (right) labeled with CellTracker Green (CTG) were cocultured with human melanoma cells labeled with CellTracker Orange (CTO) for 24 hours.
The samples were subsequently fixed and analyzed with a fluorescent microscope. suggesting that both methods can identify the same hybrid cell.
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Figure 6. Melanoma cells spontaneously fused with primary human dermal fibroblasts and monocytes. (a,b) A melanoma (CTO)-fibroblast (CTG) (a) and a melanoma (CTO)-monocyte (CTG) (b) hybrid visualized with a confocal microscope in X-Y and X-Z planes. The Zstacking confirms that double positivity does not result from cells lying on each other. Black arrows indicate the crossline of planes; white bars indicate 20 µm (a) and 10 µm (b). (c) A melanoma (CTO)-fibroblast (CTG) hybrid confirmed with confocal microscopy contains a nucleus from a female melanoma cell and another from a fibroblast from a male donor (upper row). Fluorescent in situ hybridization visualizing three X (red) and one Y (green) chromosome in the same cell (lower row). White bars indicate 30 µm (upper row) and 10 µm (lower row). (d) Fluorescent in situ hybridization visualizing two X (red) and one Y (green) chromosome in a mononucleated melanoma (female)-monocyte (male) hybrid cell. White bar
indicates 10 µm. Moreover, all hybrid cells contained one or two nuclei, but no multinucleated cells were detected. Since hybrid cells could adopt the morphology of stromal cells and, more importantly, lose the characteristic morphology of melanoma cells, we examined commonly used phenotypic markers to better characterize the CTG +/CTO + hybrid cells and to investigate whether these markers enable their discrimination from conventional stromal cells.
Interestingly, some melanoma-monocyte hybrids were positive for CD68 (Figure 11b) .
However, when the MART1-expressing G361 melanoma cell line was used, we detected hybrid cells that lost the expression of MART1 (Figure 11c-d) both in monocyte and in fibroblast co-cultures. These results provide evidence that spontaneously formed melanoma- In this study, we examined patient-derived melanoma tissue samples and detected peritumoral cells displaying stromal cell phenotype but carrying the oncogenic BRAF V600E mutation characteristic of the adjacent melanoma cells. First, we detected the mutated protein with a mutation-specific antibody. Even though nonspecific staining of the antibody in peritumoral mononuclear cells have been reported [34, 35] , the fact that peritumoral fibroblasts were also positive argues for a specific signal. Moreover, we only observed positivity in peritumoral cells adjacent to BRAF V600E melanoma but not in wild type. Nevertheless, to confirm the presence of the oncogene in these cells, we also performed genomic analyses and showed that the mutation is also present in cells with a stromal cell phenotype adjacent to BRAF V600E melanoma cells at the genetic level. We believe the mutation originates from tumor cells, as we did not detect the mutation in the stroma of BRAF WT melanoma samples. Possible [36, 37] . These studies pre-select potential hybrid tumor cells using immunohistological approaches and confirm cell fusion events using genetic analyses. Therefore, further in vitro work is needed to further characterize and identify markers unique to hybrid cells that would allow their identification in vivo as well.
We demonstrate that the fusion takes place spontaneously with fusion rates of more than 0.1%, which are surprisingly high compared to fusion rates reported in previous studies using electro-or chemical fusion followed by antibiotic selection. One possible explanation for the high fusion rates observed with flow cytometry is that most of the hybrid cells die shortly after formation [16] , partly due to mitotic stress, and they may be very sensitive to any additional stress such as antibiotics or sorting. It should be noted that fusion rates in our hands Several studies in mice [15] imply that cell fusion may also take place in human tumors in vivo. However, it is very difficult to detect tumor-stromal cell fusion on a genetic level in humans. To address this difficulty, tumors developing in patients who had received bone marrow transplants have been investigated: genetic material originating from the donor was detected in the patients' tumor cells [36, 37] , strongly suggesting a fusion event between 29 recipient tumor cells and donor hemopoietic cells. However, inflammation resulting from treatment (e.g., whole body irradiation or chemotherapeutics) preceding bone-marrow transplantation has been reported to promote cell fusion [38] [39] [40] ; therefore, further studies investigating fusion between tumor and stromal cells are clearly required.
We found that resulting hybrid cells can adopt the morphology and immunophenotype of stromal cells. Our results are in agreement with other studies proposing that tumor-stromal cell fusion can lead to the formation of hybrid cells displaying mesenchymal traits [14, 41] .
These findings highlight the fact that hybrid cells could acquire a stromal morphology and phenotype, which is especially interesting, as evidence for the presence of cell fusion in human cancer is from the detection of hybrid cells in the cancer but not the stromal compartments [36, 37, 42] .
Cell fusion studies based on in vitro observations and mouse models suggest that cell fusion might contribute to tumor progression by increasing the tumor's metastatic potential and by inducing drug resistance [23, 41, 42] to certain tumor-stromal cell hybrid clones. In addition, tumor cells can acquire stem-cell-like properties by fusing with stromal cells [14, 41] .
Therefore, cell fusion might serve as an evolutionary mechanism for tumor cells to acquiring properties that allow them to react quickly to a changing environment, such as during chemotherapy or irradiation, or even to evade immune recognition. The malignant behavior of these tumor-stromal hybrid cells in mice is supported by the finding that, even though fusion hybrids of tumor cells and multipotent stromal cells first show a predominantly mesenchymal morphology, they subsequently undergo a reversal to a cancer-like phenotype and that these hybrid cells form invasive and metastatic tumors in mice [20] . However, the majority of in vitro spontaneously formed hybrid cells undergo apoptosis [16] , most likely as a result of mitotic stress. Therefore, it is also possible that tumor-stromal cell fusion is rather an antitumor mechanism, eliminating most of the hybrid tumor cells but occasionally giving rise to highly malignant tumor cell clones. Furthermore, as our results suggest, cell fusion might provide an alternative mechanism for phenotype switching; thus, melanoma cells could become undetectable with standard histopathological methods that rely on the thorough examination of cell morphology and the expression of melanocytic markers.
Nevertheless, human in vivo studies demonstrating the relevance of tumor-stromal cell fusion in the clinical diagnosis or treatment of cancer have been missing.
In conclusion, our results suggest that peritumoral stromal cells contain melanoma-specific oncogenic properties such as the BRAF V600E mutation derived from the neighboring tumor In conclusion, these data suggest that some peritumoral stromal cells contain melanomaderived oncogenic information, potentially as a result of cell fusion. These hybrid cells display the phenotype of stromal cells and are therefore undetectable using routine histological assessments. Thus, our results highlight the importance of genetic analyses and the application of mutation-specific antibodies in the identification of potentially recurrent tumor-initiating cells, which may help better predict patient survival and disease outcome.
